Zoetis Inc. (ZTS) Stock Analysis 2026

HealthcareDrug Manufacturers - Specialty & Generic
$78.80
as of 2026-10-29
-50.1% (52-week)50D MA $75.64  |  200D MA $103.92

BriMind AI Score

Proprietary
40
Neutral
Price CAGR
5.9%
1Y Return
-44.5%
Analyst Upside
+18.5%
Rev Growth
-0.2%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

ZTS Revenue & Profitability Breakdown

This chart shows how ZTS's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$9.53B
Cost of Revenue
-$2.69B
Gross Profit
$6.83B71.7% margin
Operating Expenses
-$2.95B
Operating Income
$3.88B40.7% margin
Tax & Other
-$1.24B
Net Income
$2.64B27.7% margin
Gross Margin
71.7%
Operating Margin
40.7%
Net Margin
27.7%
EBITDA Margin
41.6%

Key Financial Metrics

Zoetis Inc. trades at a trailing P/E of 12.62x, generates $2.02B in free cash flow, runs a debt/equity ratio of 294.00, and converts shareholder equity into profit at a 64.9% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$31.96B
Enterprise Value
$80.79B
P/E (Trailing)
12.62
P/E (Forward)
11.84
PEG Ratio
6.93
EV / EBITDA
20.89
Price / Sales
8.16
Price / Book
16.31
Revenue
$9.53B
Revenue Growth
-0.2%
Earnings Growth
1.2%
EBITDA
$3.87B
Gross Margin
71.7%
Operating Margin
40.7%
Net Margin
27.7%
Return on Equity
64.9%
Return on Assets
15.4%
Free Cash Flow
$2.02B
Total Cash
$1.74B
Total Debt
$6.78B
Debt / Equity
294.00
Current Ratio
3.08
Quick Ratio
1.57
Beta
0.73
Dividend Yield
2.7%
Payout Ratio
33.6%
Insider Ownership
0.2%
Inst. Ownership
100.2%
Short % Float
4.6%
Book Value / Share
$7.84

Wall Street Analyst Consensus

16 analysts covering Zoetis Inc. currently lean toward a Buy rating, with a mean 12-month price target of $96.00 (+21.8% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingBuy(16 analysts)
SellStrong Buy
Low Target$165.00109.4%
Mean Target$96.00+21.8% upside
High Target$238.00+202.0%

Intrinsic Value Estimates for ZTS

We use 1 valuation model to estimate ZTS's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

Technical Price Signals

ZTS is currently in a short-term uptrend, trading above its 50-day average of $75.64 and below its 200-day average of $103.92. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$78.80
50-Day MA
$75.64
▲ Price above
200-Day MA
$103.92
▼ Price below
Short-term Uptrend
Above 50-day MA but mixed longer-term
Read the full ZTS in-depth report
Seven-method valuation, AI Score, blended price target, and a 5-year Monte Carlo simulation for ZTS.

Compare ZTS with Peers

ZTS vs IDXXZoetis vs IDEXX Laboratories — Animal Health Pharma vs
ZTS vs ALGNZoetis vs Align Technology — Animal Health Pharma vs Cl
CNC vs ZTSCentene vs Zoetis — Medicaid Insurer vs Animal Health P
MOH vs ZTSMolina Healthcare vs Zoetis — Medicaid Managed Care vs

Further Reading

Research and guides that put ZTS’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

FundamentalsFactor Investing Guide 2026: Value, Momentum, Quality & Low Volatility — Which Factors Work?Risk ManagementHow to Build Your First Investment Portfolio: Risk Tolerance, Asset Allocation & Your First 5 FundsFundamentalsWarren Buffett Retired 2026: Berkshire Portfolio Under Greg AbelBeginnerWhat Is an AI Stock Score? How BriMindInvest Ranks Stocks

More Healthcare Stock Analysis

In-depth reports on companies operating alongside ZTS — business models, bull and bear cases, and the metrics that matter.

PRGOPerrigo Company plcDrug Manufacturers - Specialty & GenericHIMSHims & Hers Health, Inc.Drug Manufacturers - Specialty & GenericNBIXNeurocrine Biosciences, Inc.Drug Manufacturers - Specialty & GenericISRGIntuitive Surgical, Inc.Medical Instruments & SuppliesALNYAlnylam Pharmaceuticals, Inc.BiotechnologyNVSTEnvista Holdings CorporationMedical Instruments & SuppliesINSMInsmed IncorporatedBiotechnologyMCKMcKesson CorporationMedical Distribution

Unlock the Full ZTS Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis